LX-4211 (BioDeep_00000771992)
代谢物信息卡片
Sotagliflozin
化学式: C21H25ClO5S (424.1111)
中文名称: 索格列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl
InChI: InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10669
- PubChem: 24831714
- DrugBank: DB12713
- ChEMBL: CHEMBL3039507
- CAS: 1018899-04-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Nitin J Deshmukh, M S Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V Sangle. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.
Clinical and experimental pharmacology & physiology.
2024 05; 51(5):e13854. doi:
10.1111/1440-1681.13854. [PMID: 38527859] - Bertram Pitt, Gabriel Steg, Lawrence A Leiter, Deepak L Bhatt. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
Cardiovascular drugs and therapy.
2022 06; 36(3):561-567. doi:
10.1007/s10557-021-07291-y. [PMID: 34750713] - David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
Diabetes, obesity & metabolism.
2021 12; 23(12):2632-2642. doi:
10.1111/dom.14513. [PMID: 34338408] - Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes, Marat Fudim. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.
American heart journal.
2021 03; 233(?):86-91. doi:
10.1016/j.ahj.2020.12.007. [PMID: 33385359] - Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod, David Z I Cherney, Jamie P Dwyer, Benjamin M Scirica, Clifford J Bailey, Rafael Díaz, Kausik K Ray, Jacob A Udell, Renato D Lopes, Pablo Lapuerta, P Gabriel Steg. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
The New England journal of medicine.
2021 01; 384(2):129-139. doi:
10.1056/nejmoa2030186. [PMID: 33200891] - Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato D Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
The New England journal of medicine.
2021 01; 384(2):117-128. doi:
10.1056/nejmoa2030183. [PMID: 33200892] - Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
European journal of medicinal chemistry.
2019 Dec; 184(?):111773. doi:
10.1016/j.ejmech.2019.111773. [PMID: 31630053] - Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Diabetes care.
2019 10; 42(10):1921-1929. doi:
10.2337/dc19-0937. [PMID: 31371432] - Anthony Markham, Susan J Keam. Sotagliflozin: First Global Approval.
Drugs.
2019 Jun; 79(9):1023-1029. doi:
10.1007/s40265-019-01146-5. [PMID: 31172412] - Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
BMJ (Clinical research ed.).
2019 Apr; 365(?):l1328. doi:
10.1136/bmj.l1328. [PMID: 30967375] - Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cardiovascular diabetology.
2019 02; 18(1):20. doi:
10.1186/s12933-019-0828-y. [PMID: 30819210] - John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta, Darren K McGuire, Anne L Peters, John Reed, Sangeeta Sawhney, Paul Strumph. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Diabetes care.
2018 Sep; 41(9):1970-1980. doi:
10.2337/dc18-0343. [PMID: 29937430] - Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Diabetes care.
2018 Sep; 41(9):1981-1990. doi:
10.2337/dc18-0342. [PMID: 29937431] - H Sims, K H Smith, P Bramlage, J Minguet. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association.
2018 Aug; 35(8):1037-1048. doi:
10.1111/dme.13645. [PMID: 29637608] - Paula Nogueira da Silva, Raissa Alves da Conceição, Rodolfo do Couto Maia, Maria Leticia de Castro Barbosa. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
MedChemComm.
2018 Aug; 9(8):1273-1281. doi:
10.1039/c8md00183a. [PMID: 30151080] - Thomas Danne, Torben Biester, Olga Kordonouri. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Diabetes technology & therapeutics.
2018 06; 20(S2):S269-S277. doi:
10.1089/dia.2018.0081. [PMID: 29916741] - Yao Li, Zongjun Shi, Lei Chen, Suxin Zheng, Sheng Li, Bo Xu, Zhenhong Liu, Jianyu Liu, Chongyang Deng, Fei Ye. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Journal of medicinal chemistry.
2017 05; 60(10):4173-4184. doi:
10.1021/acs.jmedchem.6b01818. [PMID: 28447791] - Matthias Kern, Nora Klöting, Michael Mark, Eric Mayoux, Thomas Klein, Matthias Blüher. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Metabolism: clinical and experimental.
2016 Feb; 65(2):114-23. doi:
10.1016/j.metabol.2015.10.010. [PMID: 26773934] - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Diabetes & vascular disease research.
2015 Mar; 12(2):101-10. doi:
10.1177/1479164114563304. [PMID: 25690134] - Brian Zambrowicz, Pablo Lapuerta, Paul Strumph, Phillip Banks, Alan Wilson, Ike Ogbaa, Arthur Sands, David Powell. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
Clinical therapeutics.
2015 Jan; 37(1):71-82.e12. doi:
10.1016/j.clinthera.2014.10.026. [PMID: 25529979] - Dídac Mauricio. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Medicina clinica.
2013 Sep; 141 Suppl 2(?):31-5. doi:
10.1016/s0025-7753(13)70061-7. [PMID: 24444522] - Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A Boehm, Dennis Ruff, David Powell, Arthur Sands. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Clinical therapeutics.
2013 Aug; 35(8):1162-1173.e8. doi:
10.1016/j.clinthera.2013.06.011. [PMID: 23911260] - Pablo Lapuerta, Julio Rosenstock, Brian Zambrowicz, David R Powell, Ike Ogbaa, Joel Freiman, William T Cefalu, Phillip Banks, Kenny Frazier, Mike Kelly, Arthur Sands. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.
Clinical cardiology.
2013 Jul; 36(7):367-71. doi:
10.1002/clc.22125. [PMID: 23630033] - David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz, Zhi-Ming Ding. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
The Journal of pharmacology and experimental therapeutics.
2013 May; 345(2):250-9. doi:
10.1124/jpet.113.203364. [PMID: 23487174] - Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands, David Powell. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Clinical therapeutics.
2013 Mar; 35(3):273-285.e7. doi:
10.1016/j.clinthera.2013.01.010. [PMID: 23433601] - B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
Clinical pharmacology and therapeutics.
2012 Aug; 92(2):158-69. doi:
10.1038/clpt.2012.58. [PMID: 22739142]
